FDA granted priority review for atezolizumab (MPDL3280A) for the treatment of people with locally advanced or metastatic non-small cell lung cancer whose disease expresses the protein PD-L1, as determined by an FDA-approved test, and who have progressed on or after platinum-containing chemotherapy. “In a study of atezolizumab in people with previously treated advanced lung cancer,...
In this episode of In the Headlines, former NCI Director Kimryn Rathmell speaks with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, about the HHS layoffs and their potential impact on mental health. These layoffs—and the broader uncertainty introduced by the current administration’s actions—are a form of trauma, Rathmell says.
